Private Equity Group Buys eClinical Firm Bracket

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical data acquisition

Private Equity Group Buys Bracket
Private Equity Group Buys Bracket
Private equity group Parthenon Capital Partners has acquired eClinical services firm Bracket from US pharmacy benefit management organization Express Scripts.

The deal – terms of which were not disclosed – will give Bracket the autonomy and resources it needs to grow in the eClinical software and services sector according to company president Catherine Spear.

Bracket – which claims to have worked on more than 1,100 clinical trials – was founded in 2011​ when United BioSource (UBC) merged its clinical technologies and specialty clinical services group into an organisation providing clinical data integrity and collection technologies and services.

The eClinical services company then became part of Express Scripts in 2012 when it bought UBC’s owner, PBM Medco, for $29bn (€21bn) in a deal that - at the time - prompted some observers to speculate that the pharmacy management group would sell Bracket​ as it did not fit with its core business.

In a press statement announcing the new deal David Ament, managing partner at Parthenon, said the acquisition of Bracket followed analysis of trends in the sector

We have been studying the clinical trials specialty services market for several years and believe Bracket offers a unique and highly compelling set of solutions to the industry.​”

This was echoed by Bradley Sloan, Principal at Parthenon, who said: “We believe life sciences companies will continue to increase their utilization of technology enabled solutions designed to optimize trial efficiency and ensure data integrity.

Bracket is well positioned to further its market leadership in these areas and help increase precision in clinical trials for years to come​.”

Virtual trials

Parthenon's comments fit with renewed sponsor and CRO interest in remote data collection and virtual trials, which had taken a bit of a hit following the recruitment problems encountered by Pfizer with its virtual OAB trial.

The turnaround began in November 2012 when Pfizer announced it was considering restarting the study this year​.

And while this restart has not yet happened, the US drugmaker’s positive mood was accompanied by a wave on interest in firms with virtual trial capabilities, with inVentiv’s investment in Mytrus in March​ being the obvious example. China’s Wuxi has also beefed up its virtual trial capabilities​.

Related news

Show more

Related products

show more

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more